• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • br In conclusion TP mutations are associated with


    In conclusion, TP53 mutations are associated with better OS, under ICI treatment in aNSCLC patients compared to patients harboring TP53-wild-type tumors. A putative predictive value of TP53 mutational status should be further assessed in a validation cohort or prospective ran-domized clinical trial with a control arm devoid of immunotherapy. Moving forward, future studies should attempt to validate a predictive signature of response to ICI, integrating altogether PD-L1 Fer 1 and TP53 mutational status as positive factors and STK11, EGFR or PTEN mutations as negative factors.
    G. Zalcman declare grants and personal fees for its Institution from Pfizer, Roche,
    BMS, MSD, Astra-Zeneca, Boerhinger but not in relation to this submission.
    V. Gounant declare personal fees from Roche, Astra-Zeneca, Lilly, BMS but not in relation to this submission
    A. Cazes declare personal fees from BMS, Roche and MSD but not in relation to this submission
    Appendix A. Supplementary data
    [3] M. Reck, D. Rodríguez-Abreu, A.G. Robinson, R. Hui, T. Csőszi, A. Fülöp, et al., Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer,
    [9] H. Rizvi, F. Sanchez-Vega, K. La, W. Chatila, P. Jonsson, D. Halpenny, et al., Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand (PD-L)-ligand 1 blockade in patients with nonsmall- cell lung cancer profiled with targeted next-generation sequencing, J. Clin. Oncol. 36 (2018) 633–641.
    [10] F. Skoulidis, L.A. Byers, L. Diao, V.A. Papadimitrakopoulou, P. Tong, J. Izzo, et al., Co-occurring genomic alterations define major subsets of KRAS-mutant lung ade-nocarcinoma with distinct biology, immune profiles, and therapeutic vulner-abilities, Cancer Discov. 5 (2015) 860–877.
    C. Whittington, Evaluation of clinical endpoints as surrogates for overall survival in patients treated with immunotherapies, J. Cancer Res. Clin. Oncol. 144 (2018) 2245–2261. [26] S.L. Mushti, F. Mulkey, R. Sridhara, Evaluation of overall response rate and pro-gression-free survival as potential surrogate endpoints for overall survival in im-munotherapy trials, Clin. Cancer Res. 24 (2018) 2268–2275.
    [34] C. Fouquet, M. Antoine, P. Tisserand, R. Favis, M. Wislez, F. Commo, et al., Rapid and sensitive p53 alteration analysis in biopsies from lung cancer patients using a functional assay and a universal oligonucleotide array: a prospective study, Clin. Cancer Res. 10 (2004) 3479–3489.
    Contents lists available at ScienceDirect
    Complementary Therapies in Medicine
    journal homepage:
    Association of traditional Chinese medicine body constitution and moderate- T to-severe cancer-related fatigue in cancer patients
    a Graduate Institute of Chinese Medicine, China Medical University, Taichung City 40402, Taiwan
    b Department of Chinese Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Dalin, Chiayi 62247, Taiwan
    c Graduate Institute of Long-Term Care, Tzu Chi University of Science and Technology, Hualien City, Hualien 97005, Taiwan
    d Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5T 3M7, Canada
    e Department of Natural Biotechnology, Nanhua University, Dalin, Chiayi 62249, Taiwan
    f School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien City, Hualien 97004, Taiwan
    Traditional Chinese medicine body constitution
    Cancer-related fatigue
    Brief fatigue inventory
    Cancer patients 
    Background and purpose: Fatigue is one of the most prevalent adverse events reported by cancer patients. The aim of bulbourethral glands study was to investigate the association between traditional Chinese medicine body constitution (TCMBC) and moderate-to-severe cancer-related fatigue in cancer patients. Materials and methods: A cross-sectional study was conducted on cancer patients recruited from a regional hospital in southern Taiwan. The association between TCMBC, measured using the Constitution in Chinese Medicine Questionnaire (CCMQ) and moderate-to-severe cancer-related fatigue (based on the Taiwanese version of the Brief Fatigue Inventory score ≥ 4) was evaluated using multiple logistic regression analysis.
    Conclusion: TCMBC could be used as a clinical tool to identify cancer patients prone to experience moderate-to-severe cancer-related fatigue, and to provide Chinese medicine practitioners a basis for selecting an appropriate treatment approach based on TCMBC.
    1. Introduction
    Fatigue is one of the most prevalent adverse events reported by cancer patients, and cancer-related fatigue is defined as the feeling of extraordinary exhaustion associated with a high level of distress, dis-proportionate to patients' activity and unrelieved by sleep or rest.1 Furthermore, according to the guidelines of the National Comprehen-sive Cancer Network (NCCN), cancer-related fatigue is defined as “a distressing, persistent, subjective sense of physical, emotional, and or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportional to recent activity and interferes with usual functioning”.2